Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Recruiting 196Active not recruiting 111Completed 77Not yet recruiting 35Terminated 24Enrolling by invitation 8Withdrawn 5Suspended 2Available 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 28Neoplasms 27Prostatic Neoplasms 22Colorectal Neoplasms 16Head and Neck Neoplasms 13Pancreatic Neoplasms 12Brain Neoplasms 11Melanoma 10Neoplasm Metastasis 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Leukemia, Myeloid, Acute 7Glioblastoma 7Multiple Myeloma 6Lymphoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Leukemia 5Hematologic Neoplasms 5Sarcoma 4Lymphoma, B-Cell 4Liver Neoplasms 4Kidney Neoplasms 4

Interventions

erdafitinib 1copanlisib 1avelumab 1atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Cystoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Urinary Bladder Neoplasms × 1 year × Clear all
NCT05714826 2026-05-27

COARC

University of Texas Southwestern Medical Center

Phase NA Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT02143804 2026-04-02

exBOND

CG Oncology, Inc.

Phase 2 Withdrawn
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms

NCT07313891 2026-03-17

BOOST

Relmada Therapeutics, Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡